NCT06748079 - A Clinical Study of TQC3721 Inhalation Powder in Patients With Chronic Obstructive Pulmonary Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 3, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

TQC3721 inhalation powder

TQC3721 is a target inhibitor.

DRUG

Placebo for TQC3721 inhalation powder

Placebo without drug substance.

Trial Locations (1)

RECRUITING

West China Hospital of Sichuan University, Chengdu